Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure.
Cardiotoxicity
Children
Delphi procedure
Doxorubicin
Pharmacokinetics
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
28 05 2020
28 05 2020
Historique:
received:
29
07
2019
accepted:
19
05
2020
entrez:
30
5
2020
pubmed:
30
5
2020
medline:
10
4
2021
Statut:
epublish
Résumé
Despite its cardiotoxicity doxorubicin is widely used for the treatment of paediatric malignancies. Current treatment regimens appear to be suboptimal as treatment strategies vary and do not follow a clear pharmacological rationale. Standardisation of dosing strategies in particular for infants and younger children is required but is hampered by scarcely defined exposure-response relationships. The aim is to provide a rational dosing concept allowing for a reduction of variability in systemic therapy intensity and subsequently unforeseen side effects. Doxorubicin plasma concentrations in paediatric cancer patients were simulated for different treatment schedules using a population pharmacokinetic model which considers age-dependent differences in doxorubicin clearance. Overall drug exposure and peak concentrations were assessed. Simulation results were used to support a three round Delphi consensus procedure with the aim to clarify the pharmacological goals of doxorubicin dosing in young children. A group of 28 experts representing paediatric trial groups and clinical centres were invited to participate in this process. Pharmacokinetic simulations illustrated the substantial differences in therapy intensity associated with current dosing strategies. Consensus among the panel members was obtained on a standardised a priori dose adaptation that individualises doxorubicin doses based on age and body surface area targeting uniform drug exposure across children treated with the same protocol. Further, a reduction of peak concentrations in very young children by prolonged infusion was recommended. An approach to standardise current dose modification schemes in young children is proposed. The consented concept takes individual pharmacokinetic characteristics into account and involves adaptation of both the dose and the infusion duration potentially improving the safety of doxorubicin administration.
Sections du résumé
BACKGROUND
Despite its cardiotoxicity doxorubicin is widely used for the treatment of paediatric malignancies. Current treatment regimens appear to be suboptimal as treatment strategies vary and do not follow a clear pharmacological rationale. Standardisation of dosing strategies in particular for infants and younger children is required but is hampered by scarcely defined exposure-response relationships. The aim is to provide a rational dosing concept allowing for a reduction of variability in systemic therapy intensity and subsequently unforeseen side effects.
METHODS
Doxorubicin plasma concentrations in paediatric cancer patients were simulated for different treatment schedules using a population pharmacokinetic model which considers age-dependent differences in doxorubicin clearance. Overall drug exposure and peak concentrations were assessed. Simulation results were used to support a three round Delphi consensus procedure with the aim to clarify the pharmacological goals of doxorubicin dosing in young children. A group of 28 experts representing paediatric trial groups and clinical centres were invited to participate in this process.
RESULTS
Pharmacokinetic simulations illustrated the substantial differences in therapy intensity associated with current dosing strategies. Consensus among the panel members was obtained on a standardised a priori dose adaptation that individualises doxorubicin doses based on age and body surface area targeting uniform drug exposure across children treated with the same protocol. Further, a reduction of peak concentrations in very young children by prolonged infusion was recommended.
CONCLUSIONS
An approach to standardise current dose modification schemes in young children is proposed. The consented concept takes individual pharmacokinetic characteristics into account and involves adaptation of both the dose and the infusion duration potentially improving the safety of doxorubicin administration.
Identifiants
pubmed: 32466789
doi: 10.1186/s40360-020-00417-2
pii: 10.1186/s40360-020-00417-2
pmc: PMC7254632
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37Références
Clin Pharmacokinet. 2017 Mar;56(3):215-223
pubmed: 27641152
Cochrane Database Syst Rev. 2010 May 12;(5):CD005006
pubmed: 20464735
Cochrane Database Syst Rev. 2014 Sep 04;(9):CD006647
pubmed: 25188452
J Clin Oncol. 2000 Nov 1;18(21):3614-21
pubmed: 11054434
Clin Pharmacokinet. 2005;44(2):147-73
pubmed: 15656695
Cochrane Database Syst Rev. 2011 Jun 15;(6):CD003917
pubmed: 21678342
Eur J Clin Pharmacol. 1985;28(2):205-12
pubmed: 3987800
Ann Oncol. 2002 Apr;13(4):503-12
pubmed: 12056699
Pediatr Blood Cancer. 2017 Nov;64(11):
pubmed: 28509433
Anticancer Drugs. 2006 Apr;17(4):385-92
pubmed: 16549995
Ann Intern Med. 1979 Nov;91(5):710-7
pubmed: 496103
Cancer Chemother Pharmacol. 2002 Feb;49(2):133-41
pubmed: 11862427
J Adv Nurs. 2003 Feb;41(4):376-82
pubmed: 12581103
Cancer Chemother Pharmacol. 2013 Mar;71(3):749-63
pubmed: 23314734
J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12
pubmed: 7310648
Cancer Drug Deliv. 1987;4(3):191-9
pubmed: 3329957
Clin Pharmacokinet. 2015 Nov;54(11):1139-49
pubmed: 25925711
J Clin Oncol. 2002 Mar 15;20(6):1677-82
pubmed: 11896119
Pediatr Blood Cancer. 2013 Oct;60(10):1574-81
pubmed: 23737479
Cancer. 1993 Nov 15;72(10):3120-30
pubmed: 8221579
Pediatr Blood Cancer. 2018 Feb;65(2):
pubmed: 29077260
J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79
pubmed: 18812549
Eur J Cancer. 1996 Sep;32A(10):1652-60
pubmed: 8983270
Klin Padiatr. 2007 May-Jun;219(3):134-8
pubmed: 17525906
Cancer Chemother Pharmacol. 1990;27(3):219-25
pubmed: 2265458
Med Pediatr Oncol. 2002 May;38(5):329-37
pubmed: 11979457
Cochrane Database Syst Rev. 2016 Mar 03;3:CD005008
pubmed: 26938118
N Engl J Med. 1998 Feb 19;338(8):499-505
pubmed: 9468466
BMC Med Res Methodol. 2005 Dec 01;5:37
pubmed: 16321161
Cancer. 2003 Jun 1;97(11):2869-79
pubmed: 12767102
Pediatr Blood Cancer. 2005 Jun 15;44(7):600-6
pubmed: 15856486
J Clin Oncol. 2008 May 1;26(13):2099-105
pubmed: 18445839
Eur J Cancer. 2014 Aug;50(12):2005-9
pubmed: 24878063
Pediatrics. 2012 Dec;130(6):1003-11
pubmed: 23166343
N Engl J Med. 1991 Mar 21;324(12):808-15
pubmed: 1997853